Prestige Consumer Healthcare Inc. (PBH) Key Metrics
PBH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.36B
- Enterprise value
- $4.24B
- P/E (TTM)
- 14.0 10-yr median 14.4
- Forward P/E
- 10.5
- PEG ratio
- 1.51
- Price / sales
- 2.1 10-yr median 2.6
- Price / book
- 1.2 10-yr median 1.7
- EV / EBITDA
- 13.6 10-yr median 12.2
- Dividend yield
- —
- Beta
- 0.34
PBH key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsPBH valuation Price multiples at each fiscal year-end price.
PBH returns How much profit the business earns on the capital it uses.
PBH per-share figures Results divided by the shares outstanding at year-end.
PBH financial health Debt, liquidity and how easily interest is covered.
PBH efficiency & capital use Working capital cycle and where the cash goes.
PBH valuation history
PBH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PBH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PBH cash returned to shareholders
PBH price vs earnings per share
PBH key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.89B | $4.31B | $3.64B | $3.12B | $2.69B | $2.23B | $1.88B | $1.56B | $1.80B | $2.96B |
| Enterprise value | $3.87B | $5.25B | $4.73B | $4.43B | $4.17B | $3.71B | $3.55B | $3.33B | $3.77B | $5.12B |
| P/E ratio | 15.2 | 20.1 | 17.4 | — | 13.1 | 13.5 | 13.2 | — | 5.3 | 42.7 |
| Price / sales | 2.7 | 3.8 | 3.2 | 2.8 | 2.5 | 2.4 | 1.9 | 1.6 | 1.7 | 3.4 |
| Price / book | 1.5 | 2.3 | 2.2 | 2.2 | 1.7 | 1.6 | 1.6 | 1.4 | 1.5 | 3.6 |
| Price / free cash flow | 11.7 | 17.7 | 15.2 | 14.1 | 10.8 | 10.5 | 9.3 | 8.7 | 9.1 | 20.5 |
| Price / operating cash flow | 11.2 | 17.1 | 14.6 | 13.6 | 10.4 | 9.5 | 8.6 | 8.2 | 8.6 | 20.1 |
| EV / sales | 3.6 | 4.6 | 4.2 | 3.9 | 3.8 | 3.9 | 3.7 | 3.4 | 3.6 | 5.8 |
| EV / EBITDA | 11.7 | 14.5 | 12.7 | 563.0 | 11.6 | 11.7 | 11.2 | 33.7 | 10.6 | 16.8 |
| EV / free cash flow | 15.7 | 21.6 | 19.8 | 20.0 | 16.7 | 17.4 | 17.5 | 18.6 | 19.1 | 35.3 |
| Earnings yield | 6.6% | 5.0% | 5.7% | −2.6% | 7.6% | 7.4% | 7.6% | −2.3% | 18.8% | 2.3% |
| Free cash flow yield | 8.5% | 5.7% | 6.6% | 7.1% | 9.3% | 9.6% | 10.8% | 11.5% | 10.9% | 4.9% |
| Dividend yield | — | — | — | — | 0.2% | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 5.4% | 1.2% | 0.7% | 1.6% | 0.3% | 0.7% | 3.1% | 3.4% | 0.1% | 0.0% |
| Share price at fiscal year-end | $59.27 | $85.97 | $72.56 | $62.63 | $52.94 | $44.08 | $36.68 | $29.91 | $33.72 | $55.56 |
| Per share | ||||||||||
| Revenue per share | $22.35 | $22.72 | $22.43 | $22.60 | $21.38 | $18.64 | $18.83 | $18.74 | $19.45 | $16.53 |
| Earnings per share | $3.91 | $4.29 | $4.17 | −$1.65 | $4.04 | $3.25 | $2.78 | −$0.69 | $6.34 | $1.30 |
| Operating cash flow per share | $5.29 | $5.02 | $4.96 | $4.60 | $5.11 | $4.66 | $4.25 | $3.64 | $3.93 | $2.77 |
| Free cash flow per share | $5.06 | $4.86 | $4.77 | $4.45 | $4.92 | $4.22 | $3.96 | $3.43 | $3.69 | $2.71 |
| Cash per share | $1.31 | $1.95 | $0.93 | $1.17 | $0.53 | $0.64 | $1.85 | $0.53 | $0.61 | $0.78 |
| Book value per share | $38.74 | $36.64 | $32.98 | $29.01 | $31.03 | $26.84 | $22.90 | $21.05 | $22.02 | $15.41 |
| Tangible book value per share | −$20.39 | −$19.73 | −$23.78 | −$28.51 | −$33.40 | −$33.50 | −$36.83 | −$38.22 | −$41.52 | −$50.53 |
| Dividends per share | — | — | — | — | $0.08 | $0.06 | $0.03 | $0.06 | $0.00 | $0.00 |
| Capex per share | $0.23 | $0.16 | $0.19 | $0.16 | $0.19 | $0.44 | $0.28 | $0.20 | $0.23 | $0.06 |
| Debt per share | $21.46 | $20.85 | $22.71 | $27.40 | $29.63 | $29.93 | $34.55 | $34.54 | $37.23 | $41.12 |
| Shares outstanding | 48.7M | 50.1M | 50.2M | 49.9M | 50.8M | 50.6M | 51.1M | 52.1M | 53.5M | 53.4M |
| Change in shares outstanding | −2.7% | −0.2% | +0.6% | −1.9% | +0.5% | −1.0% | −1.8% | −2.7% | +0.3% | +0.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 10.2% | 12.3% | 13.5% | −5.4% | 14.0% | 13.0% | 12.6% | −3.1% | 33.9% | 8.9% |
| Return on invested capital (ROIC) | 8.1% | 9.2% | 9.4% | −0.6% | 8.8% | 8.4% | 7.6% | 1.8% | 7.1% | 4.8% |
| Return on assets (ROA) | 5.5% | 6.4% | 6.3% | −2.3% | 5.8% | 4.7% | 4.1% | −1.0% | 8.9% | 2.0% |
| Return on tangible assets | 28.5% | 37.0% | 44.5% | −17.0% | 52.0% | 43.9% | 31.0% | −10.1% | 94.4% | 17.7% |
| Free cash flow margin | 22.6% | 21.4% | 21.3% | 19.7% | 23.0% | 22.6% | 21.0% | 18.3% | 19.0% | 16.4% |
| Income quality (OCF / net income) | 1.35 | 1.17 | 1.19 | — | 1.27 | 1.43 | 1.53 | — | 0.62 | 2.13 |
| Financial health | ||||||||||
| Total debt | $1.05B | $1.04B | $1.14B | $1.37B | $1.51B | $1.51B | $1.77B | $1.80B | $1.99B | $2.19B |
| Cash & short-term investments | $63.9M | $97.9M | $46.5M | $58.5M | $27.2M | $32.3M | $94.8M | $27.5M | $32.5M | $41.9M |
| Net debt | $981.6M | $946.4M | $1.09B | $1.31B | $1.48B | $1.48B | $1.67B | $1.77B | $1.96B | $2.15B |
| Debt / equity | 0.55 | 0.57 | 0.69 | 0.94 | 0.95 | 1.12 | 1.51 | 1.64 | 1.69 | 2.67 |
| Debt / assets | 0.29 | 0.31 | 0.34 | 0.41 | 0.41 | 0.44 | 0.50 | 0.52 | 0.53 | 0.56 |
| Net debt / EBITDA | 2.96 | 2.61 | 2.92 | 166.19 | 4.12 | 4.68 | 5.28 | 17.92 | 5.51 | 7.07 |
| Current ratio | 3.57 | 4.20 | 3.20 | 2.44 | 2.04 | 2.21 | 2.44 | 2.37 | 2.46 | 2.06 |
| Quick ratio | 2.25 | 2.82 | 2.02 | 1.43 | 1.21 | 1.27 | 1.67 | 1.43 | 1.50 | 1.35 |
| Interest coverage | 7.3 | 7.1 | 5.1 | -0.3 | 5.1 | 3.6 | 3.0 | 0.6 | 2.0 | 2.2 |
| Working capital | $310.6M | $341.7M | $258.0M | $231.0M | $149.8M | $147.7M | $215.8M | $174.0M | $180.3M | $172.4M |
| Invested capital | $2.87B | $2.78B | $2.75B | $2.76B | $3.06B | $2.84B | $2.84B | $2.87B | $3.14B | $2.97B |
| Tangible asset value | −$993.2M | −$987.9M | −$1.19B | −$1.42B | −$1.70B | −$1.70B | −$1.88B | −$1.99B | −$2.22B | −$2.70B |
| Net current asset value | −$1.23B | −$1.12B | −$1.29B | −$1.51B | −$1.80B | −$1.80B | −$1.98B | −$2.04B | −$2.28B | −$2.75B |
| Graham number | $58.35 | $59.44 | $55.64 | — | $53.11 | $44.33 | $37.86 | — | $56.06 | $21.24 |
| Graham net-net per share | −$28.17 | −$24.96 | −$28.20 | −$32.91 | −$37.39 | −$37.45 | −$40.62 | −$41.22 | −$44.55 | −$54.09 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $4.1M | $2.9M | $1.3M | $2.9M | $0 | $0 |
| Share buybacks (net) | $156.3M | $51.5M | $25.0M | $50.0M | $2.9M | $11.9M | $56.7M | $50.0M | $1.1M | $1.4M |
| Dividend payout ratio | — | — | — | — | 2.0% | 1.7% | 0.9% | — | 0.0% | 0.0% |
| Dividends + buybacks / free cash flow | 63.4% | 21.2% | 10.4% | 22.5% | 2.8% | 6.9% | 28.7% | 29.6% | 0.5% | 1.0% |
| Capex / revenue | 1.0% | 0.7% | 0.8% | 0.7% | 0.9% | 2.4% | 1.5% | 1.1% | 1.2% | 0.3% |
| Capex / operating cash flow | 4.3% | 3.3% | 3.8% | 3.4% | 3.7% | 9.4% | 6.7% | 5.5% | 6.0% | 2.0% |
| Capex / depreciation | 0.36 | 0.27 | 0.31 | 0.24 | 0.30 | 0.74 | 0.50 | 0.33 | 0.37 | 0.12 |
| Stock-based compensation / revenue | 1.0% | 1.0% | 1.2% | 1.1% | 0.8% | 0.9% | 0.8% | 0.8% | 0.9% | 0.9% |
| SG&A / revenue | 24.4% | 23.2% | 23.1% | 22.4% | 24.4% | 23.7% | 24.5% | 23.9% | 31.9% | 24.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 64.7 | 59.5 | 55.8 | 49.6 | 42.7 | 51.3 | 56.7 | 54.2 | 48.7 | 48.0 |
| Days of inventory on hand | 108.9 | 103.9 | 109.6 | 102.6 | 92.1 | 106.5 | 104.8 | 103.6 | 92.0 | 98.9 |
| Days payables outstanding | 14.8 | 21.0 | 37.1 | 43.0 | 39.8 | 49.9 | 52.8 | 51.2 | 51.7 | 51.9 |
| Cash conversion cycle (days) | 158.9 | 142.4 | 128.3 | 109.1 | 94.9 | 107.8 | 108.7 | 106.5 | 88.9 | 95.0 |
| Receivables turnover | 5.64 | 6.13 | 6.55 | 7.36 | 8.56 | 7.11 | 6.43 | 6.74 | 7.50 | 7.60 |
| Payables turnover | 24.65 | 17.38 | 9.85 | 8.48 | 9.16 | 7.31 | 6.91 | 7.13 | 7.06 | 7.04 |
| Inventory turnover | 3.35 | 3.51 | 3.33 | 3.56 | 3.96 | 3.43 | 3.48 | 3.52 | 3.97 | 3.69 |
| Asset turnover | 0.31 | 0.34 | 0.34 | 0.32 | 0.31 | 0.27 | 0.28 | 0.27 | 0.27 | 0.26 |
| Average receivables | $193.1M | $185.5M | $171.9M | $153.2M | $127.0M | $132.6M | $149.7M | $144.8M | $138.8M | $116.0M |
| Average payables | $20.9M | $29.0M | $50.9M | $59.3M | $50.9M | $54.2M | $59.5M | $59.0M | $65.8M | $54.3M |
| Average inventory | $153.4M | $143.2M | $150.4M | $141.2M | $117.7M | $115.5M | $118.0M | $119.2M | $117.1M | $103.4M |
| Intangibles / total assets | 81.2% | 83.0% | 85.8% | 85.6% | 89.2% | 89.1% | 86.9% | 89.7% | 90.4% | 90.0% |
Computed from PBH's annual financial statements (latest annual report filed May 14, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PBH valuation and financial ratios
At the end of fiscal 2026 (March 31, 2026), Prestige Consumer Healthcare traded at 15.2 times earnings, against a 10-year median of 14.4. Based on the latest twelve months, the trailing P/E is 14.0 and the forward P/E is 10.5. Prestige Consumer Healthcare earned a return on equity of 10.2% and a return on invested capital of 8.1% in fiscal 2026. It ended the year with $1.0 billion of debt and $63.9 million in cash and short-term investments, net debt of $981.6 million. It returned $156.3 million to shareholders: $0 in dividends and $156.3 million in share buybacks, 63% of free cash flow. The share count fell 8.7% from 53.4M to 48.7M over 9 years.
See the PBH income statement, the PBH chart for price history, or the PBH stock overview for the latest quote and news.
PBH key metrics FAQ
What is Prestige Consumer Healthcare's P/E ratio?
Prestige Consumer Healthcare's trailing P/E ratio is 14.0 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 10.5. At the end of fiscal 2026 it was 15.2, compared with a 10-year median of 14.4.
What is Prestige Consumer Healthcare's EV/EBITDA?
Prestige Consumer Healthcare's enterprise value was 11.7 times EBITDA at the end of fiscal 2026 (enterprise value $3.9 billion, EBITDA $331.1 million); the current EV/EBITDA is 13.6.
What is Prestige Consumer Healthcare's return on equity?
Prestige Consumer Healthcare's return on equity (ROE) was 10.2% in fiscal 2026: net income of $190.3 million on average shareholders' equity of $1.9 billion.
What is Prestige Consumer Healthcare's ROIC?
Prestige Consumer Healthcare's return on invested capital was 8.1% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare had total debt of $1.0 billion at the end of fiscal 2026, a debt-to-equity ratio of 0.55 and $981.6 million of net debt (2.96 times EBITDA).
Does Prestige Consumer Healthcare buy back its shares?
Yes. Prestige Consumer Healthcare spent $156.3 million on net share repurchases in fiscal 2026 Shares outstanding changed −2.7% over the year, to 48.7M..
What is Prestige Consumer Healthcare's free cash flow yield?
Prestige Consumer Healthcare generated $246.4 million of free cash flow in fiscal 2026, a free cash flow yield of 8.5% on its market value at year-end ($2.9 billion).
What is Prestige Consumer Healthcare's current ratio?
Prestige Consumer Healthcare's current ratio was 3.57 at the end of fiscal 2026: current assets were 3.57 times current liabilities.